These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 25996063)

  • 21. Effects of praziquantel and artesunate on the tegument of adult Schistosoma mekongi harboured in mice.
    Jiraungkoorskul W; Sahaphong S; Sobhon P; Riengrojpitak S; Kangwanrangsan N
    Parasitol Int; 2005 Sep; 54(3):177-83. PubMed ID: 15925540
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Schistosomiasis chemotherapy.
    Thétiot-Laurent SA; Boissier J; Robert A; Meunier B
    Angew Chem Int Ed Engl; 2013 Jul; 52(31):7936-56. PubMed ID: 23813602
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Schistosomiasis control: keep taking the tablets.
    Hagan P; Appleton CC; Coles GC; Kusel JR; Tchuem-Tchuenté LA
    Trends Parasitol; 2004 Feb; 20(2):92-7. PubMed ID: 14747023
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Research progress on the action of praziquantel on voltage-gated Ca2+ channel in schistosomes].
    Zhang L; Zhou XN
    Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2008 Feb; 26(1):58-62. PubMed ID: 18637588
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Heterogeneities in anti-schistosome humoral responses following chemotherapy.
    Mutapi F
    Trends Parasitol; 2001 Nov; 17(11):518-24. PubMed ID: 11872396
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antischistosomal agents: state of art and perspectives.
    Lago EM; Xavier RP; Teixeira TR; Silva LM; da Silva Filho AA; de Moraes J
    Future Med Chem; 2018 Jan; 10(1):89-120. PubMed ID: 29235368
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Egypt's schistosomiasis control programme in the 1980s prepared the ground for the global elimination of schistosomiasis by 2030.
    Fenwick A
    Trans R Soc Trop Med Hyg; 2019 Jan; 113(1):1-3. PubMed ID: 31222345
    [TBL] [Abstract][Full Text] [Related]  

  • 28. How has the genomics era impacted schistosomiasis drug discovery?
    Oliveira G; Pierce RJ
    Future Med Chem; 2015; 7(6):685-7. PubMed ID: 25996060
    [No Abstract]   [Full Text] [Related]  

  • 29. Chemotherapeutic approaches to schistosomes: current knowledge and outlook.
    Harder A
    Parasitol Res; 2002 May; 88(5):395-7. PubMed ID: 12049454
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Praziquantel--quality, dosages and markers of resistance.
    Appleton CC; Mbaye A
    Trends Parasitol; 2001 Aug; 17(8):356-7. PubMed ID: 11685889
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Praziquantel.
    Cioli D; Pica-Mattoccia L
    Parasitol Res; 2003 Jun; 90 Supp 1():S3-9. PubMed ID: 12811543
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The development of resistance to anthelmintics: a perspective with an emphasis on the antischistosomal drug praziquantel.
    Bennett JL; Day T; Liang FT; Ismail M; Farghaly A
    Exp Parasitol; 1997 Nov; 87(3):260-7. PubMed ID: 9371092
    [No Abstract]   [Full Text] [Related]  

  • 33. Schistosomiasis: challenges for control, treatment and drug resistance.
    Fenwick A; Webster JP
    Curr Opin Infect Dis; 2006 Dec; 19(6):577-82. PubMed ID: 17075334
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ca2+ signalling, voltage-gated Ca2+ channels and praziquantel in flatworm neuromusculature.
    Greenberg RM
    Parasitology; 2005; 131 Suppl():S97-108. PubMed ID: 16569296
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metabolomics reveal alterations in arachidonic acid metabolism in Schistosoma mekongi after exposure to praziquantel.
    Chienwichai P; Tipthara P; Tarning J; Limpanont Y; Chusongsang P; Chusongsang Y; Adisakwattana P; Reamtong O
    PLoS Negl Trop Dis; 2021 Sep; 15(9):e0009706. PubMed ID: 34473691
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Target-based molecular modeling strategies for schistosomiasis drug discovery.
    Ferreira LG; Oliva G; Andricopulo AD
    Future Med Chem; 2015; 7(6):753-64. PubMed ID: 25996068
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Praziquantel for Schistosomiasis: Single-Drug Metabolism Revisited, Mode of Action, and Resistance.
    Vale N; Gouveia MJ; Rinaldi G; Brindley PJ; Gärtner F; Correia da Costa JM
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28264841
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drugs for the control of parasitic diseases: current status and development in schistosomiasis.
    Fenwick A; Savioli L; Engels D; Robert Bergquist N; Todd MH
    Trends Parasitol; 2003 Nov; 19(11):509-15. PubMed ID: 14580962
    [No Abstract]   [Full Text] [Related]  

  • 39. Evidence against rapid emergence of praziquantel resistance in Schistosoma haematobium, Kenya.
    Coles GC; Liang YS; Doenhoff MJ
    Emerg Infect Dis; 2001; 7(6):1069-70. PubMed ID: 11747748
    [No Abstract]   [Full Text] [Related]  

  • 40. [Progress of research on preparation and application of praziquantel].
    Wu DZ; Ma Z; Liu YF; Zhu WF; Ning A
    Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi; 2013 Apr; 25(2):194-6. PubMed ID: 23894845
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.